Zovighian Bernard J reported option exercise involving 23,100 shares of Edwards Lifesciences Corp at $72.68 for $1.68M on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CEO
CEO
Filed Nov 9, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$1,678,908Shares × reported price
Shares traded
23,100Common Stock
Price per share
$72.68Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
121,945Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 9, 2026, 4:29 PM ET0-day reporting delay
Accession
0001225208-26-008780Code M · Transaction 395953
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 9, 2026Sell9,184$103.39−$949,488.76Trade 395954
Nov 9, 2026Sell13,916$102.78−$1,430,290.65Trade 395955
Nov 9, 2026Option exercise23,100$0.00$0Trade 395956
4 transaction rows in this filing. Joint filers share the same rows.

EW price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
EW · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 16, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −17%1w ago −8.7%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 28, 2026. F2: This transaction was executed in multiple trades at prices ranging from $103.18 to $103.66 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F3: This transaction was executed in multiple trades at prices ranging from $102.17 to $103.16 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F4: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.